ce teriflunomide
The NIOSH Hazardous Drug List
"Immunomodulatory agents"
No
No
testosterone
Androgen
No No
Yes
tofacitinib
"Disease-modifying antirheumatic drugs, immunomodulatory agents"
No
topiramate
Anticonvulsants, miscellaneous; antimi- graine agents, miscellaneous
No
Yes
toremifene
"Estrogen agonist- Antagonists, antineoplastic agents" Antineoplastic agents
No
Yes
trametinib tretinoin triptorelin ulipristal
No No No No
No
Cell stimulants and proliferants
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Gonadotropins, antineoplastic agents
Contraceptives Gonadotropins
urofollitropin
Yes
valproate/valproic acid
Anticonvulsants, miscellaneous; an- timanic agents; antimigraine agents, miscellaneous
No
vemurafenib vigabatrin vismodegib voriconazole
Antineoplastic agents
No No No No No No
Anticonvulsants
Antineoplastic agents
Azole antifungal
warfarin
Coumarin derivatives
zidovudine
HIV nucleoside and nucleotide reverse transcriptase inhibitors
No
ziprasidone ziv-afibercept zoledronic acid
Atypical antipsychotics; antimanic agent No
No
Antineoplastic agents Bone resorption inhibitors
Yes
Yes Yes Yes
No No
zonisamide
Anticonvulsants, miscellaneous
**Previously Table 3. Group 3: Non-antineoplastic drugs that have adverse reproductive effects. ***Only an occupational developmental hazard in the third trimester of pregnancy
The following table list drugs that were either removed from the 2016 List after the 2016 update or were moved to a table that is different from the table on which they were placed in the 2016 List update. Refer to Table 4. Table 4 Changes to the Placement of Drugs from the 2016 List of Hazardous Drugs
Ergonovine
Ergonovine was never approved for use in humans by the FDA in the United States. NIOSH reviewed data from studies provided by the manufacturer and determined it is unlikely that liraglutide poses a carcino- genic, reproductive, or developmental hazard to workers in a healthcare setting and is no longer considered a hazardous drug by NIOSH. NIOSH reviewed data from studies provided by the manufacturer and de- termined it is unlikely that paliperidone poses a carcinogenic, reproductive, or developmental hazard to workers in a healthcare setting and is no longer con- sidered a hazardous drug by NIOSH.
Liraglutide
Paliperidone
Drug
Notation
Bacillus Calmette Guerin (BCG)
NIOSH removed BCG from the List because it is an infectious agent and not classified as a drug by FDA. For handling recommendations, see the drug package insert.
CPhT CONNECT
www.cphtconnect.com 44
Made with FlippingBook - PDF hosting